文献速递肝胆胰外科围术期管理与 ERAS

病理治疗反应对新辅助化疗或放化疗后胰腺癌患者的预后意义不同

Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy.
PubMed 文献 · Surgery · 2021-11-10

本研究回顾性分析2011至2017年3个中心525例接受新辅助治疗后行胰腺切除术的局限性胰腺腺癌患者,其中148例接受新辅助化疗、377例接受放化疗。放化疗组病理治疗反应优于化疗组(P < .001),但两组中位总生存相似(25.8 vs 26.4个月)。病理治疗反应评分对总生存的预后意义在化疗组与放化疗组不同。

要点

  • 放化疗组病理治疗反应优于化疗组(P < .001),但两组中位总生存相似(25.8 vs 26.4个月)。
  • 化疗组评分2较评分3与更好的总生存相关(校正风险比0.49,P = .005)。
  • 放化疗组仅合并评分0/1较评分2达统计学显著(风险比0.63,P = .006)。

核心结论

  • 局限性胰腺腺癌新辅助治疗后病理治疗反应的预后意义在接受新辅助化疗或新辅助放化疗的患者中不同。

研究设计与样本

  • 回顾性分析2011至2017年3个中心接受新辅助治疗后行胰腺切除术的局限性胰腺腺癌患者525例,化疗组148例、放化疗组377例,两组分别评估。

主要发现

  • 放化疗组治疗反应评分分布为0分10%、1分30%、2分42%、3分18%,化疗组为0分2%、1分8%、2分35%、3分55%(P < .001)。
  • 两组中位总生存相似(25.8 vs 26.4个月)。
  • 化疗组评分0/1、2、3的中位总生存分别为72.2、38.5、20.0个月;放化疗组分别为37.9、24.5、19.0个月。
  • 化疗组评分2较评分3与更好的总生存相关(校正风险比0.49,P = .005)。
  • 放化疗组仅合并评分0/1较评分2达统计学显著(风险比0.63,P = .006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathological treatment effect of resected pancreatic adenocarcinoma after neoadjuvant therapy has prognostic implications. The impact for patients who received chemotherapy alone or chemoradiotherapy is not well defined. METHODS: Patients with localized pancreatic adenocarcinoma who had pancreatectomy after neoadjuvant therapy at 3 centers from 2011 to 2017 were retrospectively analyzed. The chemotherapy and chemoradiotherapy groups were evaluated separately. RESULTS: Of 525 patients, 148 received neoadjuvant chemotherapy and 377 received chemoradiotherapy. The chemoradiotherapy group had a better treatment effect (score 0: 10%, score 1: 30%, score 2: 42%, and score 3: 18%) than the chemotherapy group (score 0: 2%, score 1: 8%, score 2: 35%, and score 3: 55%) (P < .001). Median overall survival was similar between the 2 groups (25.8 vs 26.4 months). Median overall survival for score 0/1, 2, or 3 was 72.2, 38.5, and 20.0 months in the chemotherapy group and 37.9, 24.5, and 19.0 months in the chemoradiotherapy group. Score 2 in the chemotherapy group was associated with better overall survival compared to score 3 (adjusted hazard ratio: 0.49, P = .005), whereas only combined score 0/1 reached significance over score 2 for the chemoradiotherapy group (hazard ratio: 0.63, P = .006). CONCLUSION: The prognostic significance of pathological treatment effect for localized pancreatic adenocarcinoma differs for patients receiving neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Maeda S, Mederos MA, Chawla A, et al. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Surgery. 2021. PMID: 34774289. doi:10.1016/j.surg.2021.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。